Open Collections

UBC Faculty Research and Publications

Deprescribing Proton Pump Inhibitors Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 111 explores deprescribing of proton pump inhibitors. Conclusions: Many patients take PPIs well beyond the recommended course of treatment. This incurs inconvenience, costs and potential for harms. Do not prescribe or renew PPIs without a well-documented indication and therapeutic goal. Write the indication and duration of therapy in the directions, to ensure this appears on the prescription label. Consider deprescribing PPIs after 4 weeks of treatment when symptoms have resolved. Start with reduced dose or a longer interval, switching to on-demand dosing or discontinuation when successful. Patients capable of “chasing” a dose with water to facilitate stomach emptying can consider dose-splitting to save money. Informed patient consent and a strategy to deal with recurrent symptoms enhance success. For more information, consult the high-quality resources shown below.

Item Metadata

Title
Deprescribing Proton Pump Inhibitors
Alternate Title
Therapeutics Letter 111
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2018-04
Description
Therapeutics Letter 111 explores deprescribing of proton pump inhibitors. Conclusions: Many patients take PPIs well beyond the recommended course of treatment. This incurs inconvenience, costs and potential for harms. Do not prescribe or renew PPIs without a well-documented indication and therapeutic goal. Write the indication and duration of therapy in the directions, to ensure this appears on the prescription label. Consider deprescribing PPIs after 4 weeks of treatment when symptoms have resolved. Start with reduced dose or a longer interval, switching to on-demand dosing or discontinuation when successful. Patients capable of “chasing” a dose with water to facilitate stomach emptying can consider dose-splitting to save money. Informed patient consent and a strategy to deal with recurrent symptoms enhance success. For more information, consult the high-quality resources shown below.
Subject
Adverse Effects; Deprescriptions; Gastroesophageal Reflux; Long Term Adverse Effects; Peptic Ulcer; Proton Pump Inhibitors
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433690
URI
http://hdl.handle.net/2429/85100
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International